MDMA THERAPY

Psychedelic session with diabetes and other medication: risks & tips

A psychedelic session, for example with psilocybin, raises additional questions when you have diabetes and take multiple medications. Not only because of potential interactions, but also because a session can temporarily alter your appetite, stress levels, sleep, fluid balance, and physical activity. These are precisely the factors that often already play a role in diabetes and other chronic conditions.

In this article, we outline the key considerations based on what is known in the literature and in harm reduction practices. We make a clear distinction between what is relatively well-substantiated, what is primarily to be expected as a matter of course, and what has been subjected to limited research. This is general information and not individual medical advice. Never change medication or dosages on your own initiative, but discuss this with your treating physician.

It is important to note that psychedelic sessions with substances such as psilocybin or MDMA cannot be offered as a standard treatment in the Netherlands. Currently, MDMA sessions can only be discussed within the framework of scientific research or in clinical practice through harm reduction. Precisely for this reason, thorough preparation, realistic expectations, and risk mitigation are especially important.

Why medication and underlying conditions are at least as important as “interactions”

When people ask about “interactions” between psilocybin and a list of medications, attention is often focused on one thing: can they be taken together? In practice, there is a second layer that is at least as important. A medication list often also reveals something about the health situation: diabetes management, cardiovascular risks, kidney function, inflammatory diseases, or psychological vulnerabilities. That context can determine safety more than the presence or absence of a direct pharmacological interaction.

Psychedelics can cause physical effects in the acute phase, such as a temporary increase in heart rate and blood pressure, nausea, sweating, or shivering. For many healthy people, this causes no problems, but an individual assessment may be advisable in the case of existing cardiovascular disease or unstable diabetes. Additionally, anxiety or restlessness during a difficult phase of a session can amplify physical stress, which can affect glucose levels in people with diabetes.

Diabetes in a psychedelic session: what can practically change?

In diabetes, safety often revolves around predictability: eating, exercising, insulin, and medication in a more or less stable pattern. A psychedelic session can temporarily break that pattern. These are practical changes that are frequently mentioned:

Appetite and timing of eating
Some people eat less due to nausea or distraction. Others, conversely, get hungry later. This can make it more difficult to prevent hypoglycemia or to properly adjust insulin to intake.

Physical activity
During a session, one sometimes moves more (walking, pacing restlessly) or, conversely, lies still for a long time. Both can affect glucose.

Stress response
An intense moment can increase adrenaline and cortisol. This can (temporarily) increase glucose. For others, eating less or exercising more can actually lead to hypoglycemia. The direction is therefore not the same for everyone.

Moisture balance
Sweating, drinking less, or conversely drinking a lot of water without electrolytes can cause problems. Dehydration is particularly relevant with certain diabetes medications.

The core message: with diabetes, it is wise to have a concrete safety plan in place beforehand, especially when you are alone or when your guide does not know what to do in the event of a hypo.

Medication by category: what is known, what is uncertain?

Below are the agents mentioned in the source context, with the appropriate nuances. “No known direct interaction” does not mean “no risk”. It means that no clear, well-substantiated pharmacological conflict has been described. The main risks then often lie in indirect effects, context, and comorbidity.

Insulin (general) and Levemir (insulin detemir)
No known direct interactions have been described for insulin and psilocybin. However, the most important point of attention is the risk of hypo- or hyperglycemia, as your eating patterns, activity, and stress levels may change. With long-acting insulin (such as detemir), the background effect is present even if you eat less. This is precisely the kind of situation where monitoring beforehand and a plan for fast sugars can be important.

Metformin
Metformin itself usually does not cause hypoglycemia. There are no known direct interactions with psilocybin. In practice, it mainly concerns general session factors: nausea, reduced appetite, and dehydration can make it physically more difficult. If you experience gastrointestinal issues, this can also have a psychological impact on the experience.

Forxiga (dapagliflozin, SGLT2 inhibitor)
There is no known direct interaction with psilocybin. However, extra attention to fluid balance is important, as SGLT2 inhibitors increase glucose excretion in the urine and can thereby promote dehydration. In diabetes, dehydration is not only unpleasant, but it can also affect your overall physical capacity. Here too, it is important to discuss your personal risk profile with your doctor, especially if you are prone to dehydration or have impaired kidney function.

Mounjaro (tirzepatide)
No direct interactions are known for tirzepatide and psilocybin. However, tirzepatide can delay gastric emptying. A logical consequence is that the onset of an orally administered substance may be delayed or feel different than expected. Nausea and other gastrointestinal complaints may also become more prominent. This is not necessarily dangerous, but it can make the experience more intense or uncomfortable, and it can make your timing around eating and glucose management more difficult.

Ascal (acetylsalicylic acid)
There is no known direct interaction with psilocybin. A point of attention that often applies more broadly: psilocybin can temporarily increase heart rate and blood pressure during the peak. This is independent of Aspirin, but is relevant if Aspirin is being used due to a cardiovascular history. In that case, it is less about the combination with Aspirin and more about the reason why you are using Aspirin.

Pantoprazole
No clinically relevant interactions between pantoprazole and psilocybin are known. At most, the topic of “stomach complaints” may resurface: if you are using pantoprazole for reflux or stomach problems, nausea during a session can be particularly unpleasant.

Methotrexate
There is little targeted research into this. Based on current knowledge, no direct interactions are expected, but uncertainty is greater than with agents with which there is more experience. Methotrexate is often used for inflammatory diseases. This means that your overall physical capacity, fatigue, and any liver or kidney checks are part of your medical context. That is exactly the kind of background information you want to include in a safety assessment with your healthcare provider.

Rosuvastatin
There are no known direct interactions with psilocybin, and this combination is generally considered low-risk. Again, it applies that the reason for use (cholesterol, cardiovascular risk) can be relevant for assessing cardiovascular strain during an intense experience.

Brintellix (vortioxetine)
Antidepressants can reduce the subjective effects of psychedelics. This is also mentioned in relation to vortioxetine, although the exact degree is person-dependent and not always easy to predict. The topic of serotonin syndrome is sometimes mentioned in connection with combinations of serotonergic agents, but well-documented cases specifically for vortioxetine with psilocybin are scarce. Scarcity of reports is not the same as proof of absence, so caution remains appropriate. Adjusting or discontinuing medication should only be done in consultation with the prescribing physician, partly due to withdrawal symptoms and the recurrence of symptoms.

Lorazepam
Benzodiazepines such as lorazepam can significantly flatten or “cut short” the psychedelic experience. This can sometimes be perceived as reassuring, but it can also diminish the intended depth. Some people notice less sedation if they do not use for a few days beforehand, but here too, the rule applies: this is not a do-it-yourself adjustment. Benzodiazepines can cause dependence and rebound anxiety, and stopping or pausing is the responsibility of the prescribing physician.

Practical harm-reduction tips for diabetes and polypharmacy

The tips below are general and intended as preparation and risk reduction, not as a personal treatment plan.

1) Make a “glucose plan” in advance”
Consider: how often do you want to measure, which values are an alarm signal for you, and what is the agreed action in the event of a (looming) hypo or hyper? If you use a sensor, check beforehand whether notifications are enabled and whether you have spare parts.

2) Ensure that a sober supervisor knows what to do.
Someone you trust who remains sober can help with practical matters such as measuring blood sugar, offering drinks, and recognizing hypo signals. Agree on where fast carbohydrates are located and when medical help should be called.

3) Take nausea and delayed onset into account
Especially when using medications that affect gastric emptying (such as tirzepatide), the timeline may unfold differently than expected. Anxiety often arises when people “jump to conclusions too quickly” and, for example, redose before the first dose has fully taken effect. Redosing creates additional uncertainty.

4) Pay attention to hydration, but don't overdo it
Taking regular small sips can be more pleasant than large amounts at once. This is especially relevant when using medication that can promote dehydration. Drinking excessive water without salt or food can also have disadvantages, certainly during long sessions. A normal, steady fluid intake is usually a sensible baseline.

5) Discuss your situation with your treating physician
With multiple medications, it is not just about interactions, but also about your overall risk profile. In any case, discuss diabetes management, kidney function, cardiovascular disease, and any previous complications. A doctor cannot give “approval” for illegal substance use, but can often help map out medical risks.

6) Be realistic about outcome expectations
Sometimes the idea prevails that a psychedelic session is by definition therapeutic or healing. Research shows promising results for some indications, but outcomes are variable and strongly dependent on the set, setting, guidance, and individual factors. A difficult experience is not automatically bad, but it does require proper aftercare and integration.

When extra caution is advisable

There are situations in which it may be wise to postpone a session or only consider it with additional medical consultation. Examples include unstable glucose levels, recent hypo-unawareness, severe kidney problems, known cardiovascular disease, or a period of severe psychological dysregulation. Polypharmacy in itself is also a signal not to think too simplistically: “No interaction found, so it is safe.”

If you are considering discussing this in a supervised setting, it is important to know that MDMA sessions can currently only take place within scientific research or in practice via harm reduction. For psilocybin, the legal status and practical context are different, but there too, a careful, sober risk assessment remains essential.

Conclusion

During a psychedelic session with diabetes and an extensive medication list, there are often few hard indications of direct interactions with psilocybin, but the indirect risks can be particularly significant. Consider hypo- or hyperglycemia due to altered appetite and activity, dehydration associated with certain substances, nausea, and an altered timeline of onset. The safest course of action is to discuss your overall health situation with your treating physician and create a concrete plan for monitoring and support.

Would you like to explore how guided sessions in a harm-reduction context are typically prepared and what questions you can ask? If so, you can sign up for an exploratory contact via https://mdmatherapie.nl/aanmelden-mdma-sessie/.